Spots Global Cancer Trial Database for cyclophosphamid

Every month we try and update this database with for cyclophosphamid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.	NCT05990985	Diffuse Large B...	Mitoxantrone hy... RiTUXimab Injec... Cyclophosphamid Vincristine Prednisolone	18 Years -	The First Hospital of Jilin University
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma	NCT04706936	Relapsed or Ref...	anti-BCMA CAR-T Cyclophosphamid Fludarabine	18 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)	NCT01690325	Breast Cancer	Docetaxel Trastuzumab Bevacizumab Epirubicin Cyclophosphamid	18 Years - 65 Years	West German Study Group
Natural Killer (NK) Cell Therapy for B-Cell Malignancies	NCT05379647	B-cell Lymphoma B-cell Acute Ly...	QN-019a Rituximab Cyclophosphamid Fludarabine VP-16	18 Years -	Zhejiang University
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients	NCT05580887	Breast Cancer Pancreas Cancer	mFOLFIRINOX Doxorubicin Cyclophosphamid Paclitaxel Carboplatin	18 Years - 80 Years	Moscow Clinical Scientific Center
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning	NCT03852407	Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom...	Thymoglobulin Melphalan Fludarabine Cyclophosphamid	18 Years - 75 Years	University of Liege
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade	NCT06238245	Graft-versus-ho... Hematological M...	Cyclophosphamid	18 Years -	Beijing 302 Hospital
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma	NCT04706936	Relapsed or Ref...	anti-BCMA CAR-T Cyclophosphamid Fludarabine	18 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer	NCT04611126	Metastatic Ovar... Metastatic Fall... Peritoneal Canc...	Ipilimumab Cyclophosphamid Fludarabine Pho... Tumor Infiltrat... Nivolumab Relatlimab	18 Years - 75 Years	Herlev Hospital
CD30 CAR for CD30+ NSGCT	NCT05634785	Germ Cell Tumor Nonseminomatous...	ATLCAR.CD30 Cel... Cyclophosphamid Fludarabine	18 Years -	UNC Lineberger Comprehensive Cancer Center
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia	NCT05665075	AML, Adult	QN-023a Cyclophosphamid Fludarabine Cytarabine VP-16	18 Years -	Zhejiang University
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia	NCT05601466	AML, Adult	QN-023a Cyclophosphamid Fludarabine Cytarabine	18 Years -	Institute of Hematology & Blood Diseases Hospital, China
ATG Plus Low-dose PT-Cy for GVHD Prevention	NCT06108739	Hematologic Mal...	Cyclophosphamid ATG	12 Years - 55 Years	Peking University People's Hospital
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia	NCT05665075	AML, Adult	QN-023a Cyclophosphamid Fludarabine Cytarabine VP-16	18 Years -	Zhejiang University
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study	NCT05656079	Breast Cancer	Pegylated lipos... Epirubicin Cyclophosphamid Trastuzumab Pertuzumab Docetaxel	18 Years - 70 Years	Shanghai Pudong Hospital
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease	NCT05601830	Minimal Residua...	QN-030a Cyclophosphamid Fludarabine Cytarabine	18 Years -	Institute of Hematology & Blood Diseases Hospital, China
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease	NCT05601830	Minimal Residua...	QN-030a Cyclophosphamid Fludarabine Cytarabine	18 Years -	Institute of Hematology & Blood Diseases Hospital, China
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer	NCT04576143	HER2-negative B... Neoadjuvant Che...	Epirubicin Cyclophosphamid Docetaxel Paclitaxel	18 Years - 70 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)	NCT01690325	Breast Cancer	Docetaxel Trastuzumab Bevacizumab Epirubicin Cyclophosphamid	18 Years - 65 Years	West German Study Group
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer	NCT04576143	HER2-negative B... Neoadjuvant Che...	Epirubicin Cyclophosphamid Docetaxel Paclitaxel	18 Years - 70 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies	NCT04943757	Myeloid Leukemi... Chronic Myeloid... Myelodysplastic... Myeloproliferat...	Bendamustine Hy... Cyclophosphamid	18 Years - 70 Years	St. Petersburg State Pavlov Medical University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: